| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $2,004,246 ) |
| | 2024 | 2024 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | P20GM135009 | Oklahoma Center of Medical Imaging for Translational Cancer Research | 000 | 3 | NIH | 1/3/2024 | $2,035,962 |
| | 2024 | 2024 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01GM152704 | Development of protein-based nanostructures activated by ultrasound | 000 | 1 | NIH | 1/15/2024 | $363,919 |
| | 2024 | 2024 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01NS123051 | Single stage surgical intervention for treatment of severe traumatic brain injury | 001 | 3 | NIH | 2/23/2024 | $79,922 |
| | 2024 | 2024 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01NS123051 | Single stage surgical intervention for treatment of severe traumatic brain injury | 000 | 3 | NIH | 2/22/2024 | $544,518 |
| | 2024 | 2024 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01GM138800 | A Chemoenzymatic Approach to Accessing Novel Isoprenoid Scaffolds | 000 | 3 | NIH | 12/1/2023 | $261,643 |
| | 2024 | 2024 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R03AI175981 | Characterizing mechanisms of immune protection by the bacterial type II-A CRISPR systems | 000 | 1 | NIH | 12/12/2023 | $63,891 |
| | 2024 | 2024 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01CA269897 | Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors | 001 | 3 | NIH | 4/17/2024 | $24,475 |
| | 2024 | 2024 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01CA269897 | Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors | 000 | 3 | NIH | 3/8/2024 | $440,527 |
| | 2024 | 2024 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01AI132836 | Permeability barriers of Gram-negative pathogens and approaches to bypass them | 000 | 7 | NIH | 4/16/2024 | $463,073 |
| | 2024 | 2024 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01DC011579 | Taste and Somatosensory Processing | 000 | 13 | NIH | 2/5/2024 | $342,645 |
| | 2024 | 2024 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01AI052293 | Transport across two membranes by AcrAB-TolC | 000 | 20 | NIH | 3/15/2024 | $493,895 |
| | 2024 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | U01MD017700 | The Effect of Medicaid Expansion on Mortality Disparities and Poverty | 000 | 2 | NIH | 10/10/2023 | $0 |
| | 2024 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01GM145649 | An LCMS-guided bioanalytical approach for rational natural product library design and optimization | 000 | 2 | NIH | 3/19/2024 | -$38,862 |
| | 2024 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01GM145649 | An LCMS-guided bioanalytical approach for rational natural product library design and optimization | 000 | 2 | NIH | 3/19/2024 | -$249,446 |
| | 2024 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | H79SP083220 | Strategic Prevention Framework for Prescription Drugs | 000 | 2 | SAMHSA | 10/31/2023 | $0 |
| | 2024 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01AI170605 | Deciphering the mechanism of action of carnitine, a novel treatment for chronic Chagas disease | 000 | 2 | NIH | 4/22/2024 | -$291,099 |
| | 2024 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | 90YR0133 | Happy Teacher Wellness Program to Support Head Start Staff's Well-Being | 02 | 3 | ACF | 4/23/2024 | $0 |
| | 2024 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | 90YR0133 | Happy Teacher Wellness Program to Support Head Start Staff's Well-Being | 01 | 3 | ACF | 11/2/2023 | $0 |
| | 2024 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | H79SP080985 | Implement and evaluate the Region 6 Prevention and Technology Transfer Center (PTTC) project for Health and Human Service Region 6, by providing high-impact training and technical assistance services. | 001 | 5 | SAMHSA | 2/12/2024 | $0 |
| | 2024 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | H79SP080985 | Implement and evaluate the Region 6 Prevention and Technology Transfer Center (PTTC) project for Health and Human Service Region 6, by providing high-impact training and technical assistance services. | 000 | 5 | SAMHSA | 10/20/2023 | $0 |
| | 2024 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | P30GM145423 | Oklahoma COBRE in Structural Biology | 000 | 2 | NIH | 11/16/2023 | $0 |
| | 2024 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | 90FA3011 | Promoting parent and child well-being and reducing the need for foster care: An evaluation of a one-year, home-visiting and case management program for people using substances during pregnancy | 01 | 1 | ACF | 10/18/2023 | $0 |
| | 2024 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01AI177469 | Novel single-cell mass spectrometry methods to assess the role of intracellular drug concentration and metabolism in antimicrobial treatment failure | 000 | 1 | NIH | 3/5/2024 | -$494,482 |
| | 2024 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01HD109157 | Shift from Unilateral to Bilateral Sensory-Motor Connectivity in Chronic Hemiparetic Stroke | 000 | 2 | NIH | 1/11/2024 | -$324,876 |
| | 2024 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | U01MD017700 | The Effect of Medicaid Expansion on Mortality Disparities and Poverty | 001 | 2 | NIH | 2/8/2024 | -$329,606 |
| | 2024 | 2022 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | 90YR0142 | Exploring Variations Among Head Start Dual Language Learners: What Factors Predict Different Longitudinal Developmental Patterns | 05 | 1 | ACF | 2/14/2024 | $0 |
| | 2024 | 2022 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | 90YR0142 | Exploring Variations Among Head Start Dual Language Learners: What Factors Predict Different Longitudinal Developmental Patterns | 04 | 1 | ACF | 11/13/2023 | $0 |
| | 2024 | 2022 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01AI136799 | Optimization of efflux avoidance and inhibition for antibiotic development | 000 | 5 | NIH | 4/4/2024 | $0 |
| | 2024 | 2021 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01CA205348 | Mechanistic study on synergistic photo-immunological effects of laser immunotherapy for metastatic cancers | 000 | 5 | NIH | 2/28/2024 | $0 |
| | 2024 | 2021 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | P20GM103640 | Oklahoma COBRE in Structural Biology | 000 | 10 | NIH | 12/1/2023 | -$1,357,636 |
| | 2024 | 2021 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R21AI148886 | Oral carnitine administration as a novel treatment for chronic-stage Chagas disease | 000 | 2 | NIH | 1/8/2024 | -$14,468 |
| | 2024 | 2020 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01GM120634 | Structural Transitions in Proteins and Protein Assemblies | 000 | 4 | NIH | 1/10/2024 | -$9,749 |
|
| Issue Date FY: 2023 ( Subtotal = $18,564,403 ) (Continued on the next page) |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R03AI166402 | Universal Anti-PAMP Agent to Improve Wound Healing | 000 | 2 | NIH | 5/5/2023 | $73,949 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01CA218739 | Endogenous fluorescence lifetime endoscopy for early detection of oral cancer and dysplasia | 000 | 7 | NIH | 8/3/2023 | $288,816 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01GM138592 | Defining the mechanistic determinants of catalytic bias in cofactor-based enzymatic oxidation-reduction reactions | 002 | 5 | NIH | 8/11/2023 | $334,328 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01AI132836 | Permeability barriers of Gram-negative pathogens and approaches to bypass them | 000 | 6 | NIH | 4/19/2023 | $463,073 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | RM1HG009042 | Center on the Ethics of Indigenous Genomic Research | 000 | 8 | NIH | 6/30/2023 | $881,674 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 1000 ASP AVE RM 105 | NORMAN | OK | 73019-4039 | CLEVELAND | USA | R01NS123051 | Single stage surgical intervention for treatment of severe traumatic brain injury | 000 | 2 | NIH | 3/1/2023 | $588,831 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01NS123051 | Single stage surgical intervention for treatment of severe traumatic brain injury | 001 | 2 | NIH | 4/11/2023 | $79,922 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 1000 ASP AVE RM 105 | NORMAN | OK | 73019-4039 | CLEVELAND | USA | R01AI052293 | Transport across two membranes by AcrAB-TolC | 000 | 19 | NIH | 3/28/2023 | $493,885 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01AI170605 | Deciphering the mechanism of action of carnitine, a novel treatment for chronic Chagas disease | 000 | 2 | NIH | 6/21/2023 | $421,656 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R35GM150970 | Enabled by drug delivery: Studying the role of brain-resident and infiltrating myeloid cell phenotype in brain damage associated with inflammatory disease | 000 | 1 | NIH | 7/26/2023 | $373,297 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R35GM150970 | Enabled by drug delivery: Studying the role of brain-resident and infiltrating myeloid cell phenotype in brain damage associated with inflammatory disease | 001 | 1 | NIH | 9/1/2023 | $0 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R00ES033257 | Linking genomic, physiological, and behavioral responses using a Drosophila model of heavy metal stress | 000 | 3 | NIH | 8/8/2023 | $248,958 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R21EY034326 | Characterizing the prevalence and nature of facial recognition deficits in non-proliferative diabetic retinopathy | 001 | 1 | NIH | 7/14/2023 | $0 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R21EY034326 | Characterizing the prevalence and nature of facial recognition deficits in non-proliferative diabetic retinopathy | 000 | 1 | NIH | 5/26/2023 | $192,082 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R35GM151086 | Epigenetic and transcriptional mechanisms driving human pigmentation diversity | 000 | 1 | NIH | 8/22/2023 | $373,297 |
| | 2023 | 2023 | UNIVERSITY OF OKLAHOMA | 660 PARRINGTON OVAL RM 301 | NORMAN | OK | 73019-3003 | CLEVELAND | USA | R01AI177469 | Novel single-cell mass spectrometry methods to assess the role of intracellular drug concentration and metabolism in antimicrobial treatment failure | 000 | 1 | NIH | 6/27/2023 | $494,483 |
|
